Abingdon Health completes FDA’s Section IVD process for rapid COVID-19 test

Abingdon Health, a UK-based developer and manufacturer of lateral flow tests and smartphone reader solutions, has been notified by the US Food and Drug Administration (FDA) that it has completed the Section IV.D notification process.

Show CommentsClose Comments

Leave a comment

%d bloggers like this: